You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils

Radionuclide Therapy for Patients with Neuroendocrine Tumors (NETs) in Ontario: Expert Panel Report

ID: GL-C50-01 jan 2011
Type of Content: Guidelines & Advice, Health System
Document Status: Current
Expert Panel

Guideline Objective

Cancer Care Ontario struck the Ontario Neuroendocrine Expert Panel to develop recommendations for the organization and delivery of radionuclide (RN) therapy for NET patients in Ontario. The work was supported by Cancer Care Ontario’s Program in Evidence-Based Care (PEBC) division, who performed a formal search for evidence to support these guidelines, and for existing guidelines in other jurisdictions. Data sources available to Cancer Care Ontario were also used to provide information on current patterns of care.

Intended Guideline Users

Physicians and Health Care Administrators